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Screening for specific biomarkers of early-stage detection of ovarian cancer is a major health priority due to the asymptomatic nature
and poor survival characteristic of the disease. We utilised two-dimensional gel electrophoresis (2DE) to identify differentially
expressed proteins in the serum of ovarian cancer patients that may be useful as biomarkers of this disease. In this study, 38 ovarian
cancer patients at different pathological grades (grade 1 (n¼6), grade 2 (n¼8) and grade 3 (n¼24)) were compared to a control
group of eight healthy women. Serum samples were treated with a mixture of Affigel-Blue and protein A (5:1) for 1h to remove
high abundance protein (e.g. immunoglobulin and albumin) and were displayed using 11cm, pH 4–7 isoelectric focusing strips for the
first dimension and 10% acrylamide gel electrophoresis for the second dimension. Protein spots were visualised by SYPRO-Ruby
staining, imaged by FX-imager and compared and analysed by PDQuest software. A total of 24 serum proteins were differentially
expressed in grade 1 (Po0.05), 31 in grade 2 (Po0.05) and 25 in grade 3 (Po0.05) ovarian cancer patients. Six of the protein spots
that were significantly upregulated in all groups of ovarian cancer patients were identified by nano-electrospray quadrupole
quadrupole time-of-flight mass spectrometry (n-ESIQ(q)TOFMS) and matrix-assisted laser desorption ionisation time-of-flight mass
spectrometry (MALDI-TOFMS) as isoforms of haptoglobin-1 precursor (HAP1), a liver glycoprotein present in human serum. Further
identification of the spots at different pathological grades was confirmed by Western blotting using monoclonal antibody against a
haptoglobin epitope contained within HAP1. Immunohistochemical localisation of HAP1-like activity was present in malignant ovarian
epithelium and stroma but strong immunostaining was present in blood vessels, areas with myxomatous stroma and vascular spaces.
No tissue localisation of HAP1-like immunoreactivity was observed in normal ovarian surface epithelium. These data highlight the
need to assess circulating concentration of HAP1 in the serum of ovarian cancer patients and evaluate its potential as a biomarker in
the early diagnosis of ovarian cancer.
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Epithelial ovarian cancer is associated with a high mortality rate
despite the high cure rate for early-stage disease by surgical
resection alone. This discrepancy between the high mortality rate
and cure at an early stage occurs predominantly due to advanced
stage presentation due to lack of symptoms at an early stage
(Greenlee et al, 2001). Approximately 75% of women present with
ovarian cancer at stage 3, when the cancer has spread beyond the
pelvis and 5-year survival is only 29% (Landis et al, 1999). Over the
past 10 years considerable progress has been made in optimising
the adjuvant therapy, but these advancements have resulted in
modest improvement in disease-free and overall survival. Yet, the
mortality from ovarian cancer can be significantly reduced by the
application of an effective screening technique at an early stage. To
date, despite extensive research and evaluation, the combination of
physical examination, imaging with transvaginal ultrasound, and
detection and monitoring of the disease using serum marker CA
125 have not resulted in acceptable sensitivity of early-stage
ovarian cancer screening. Hence, to save lives from ovarian cancer,
there is an urgent need to identify new markers in the serum of
early-stage patients.
The serum CA 125 antigen concentration is the ‘gold standard’ for
ovarian cancer tumour markers (Lloyd and Yin, 2001). Although this
protein was identified 20 years ago its structure and function has not
been elucidated (Jacobs et al, 1999). With a cutoff of 30–35Uml
 1,
the sensitivity for CA 125 for early-stage ovarian cancer is 50–60%.
Moreover, CA 125 concentrations are elevated in women with benign
gynaecologic conditions, including ovarian cysts, endometriosis and
uterine fibroids, which are part of the differential diagnosis for
ovarian cancer (Mogensen, 1992; Cannistra, 1993; Mackey and
Creasman, 1995). In some cases, women with hepatic disease, renal
failure, pancreatitis or other conditions may have elevated CA 125
making the usefulness of CA 125 as a marker for early detection
limited (Bastani and Chu, 1995; Devarbhavi et al, 2002). In recent
years, several serum markers have been identified and explored as
possible adjuncts to CA 125 screening. Unfortunately, these markers,
including CA19-9 and lysophosphatidic acid, have not shown to be
clinically relevant in large screening trials (Woolas et al, 1999).
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yProteomics is a new and emerging technology that can identify
protein molecules in a high-throughput discovery approach in
patient’s serum, biofluids and tissues providing information about
which proteins are secreted or released from tumour cells at
sufficient concentrations. Recently, the serological proteomic
pattern of the ovarian cancer patients has been described that
discriminates cancerous from noncancerous groups with a positive
predictive value of 94% (Petricoin et al, 2002). This approach
represents a novel direction in the search for biomarkes for early-
stage screening of ovarian cancer wherein a distinct profile of
proteins from early-stage cancer patients can create a discrimina-
tory pattern of proteins that can be used as a diagnostic standard.
Alternatively, a small subset of differentially expressed proteins
from a large volume of profiling data can be identified and these
proteins can serve as biomarkers and can be used as targets for
further development in molecular diagnostics and therapeutics.
Electrospray ionisation mass spectrometry, matrix-assisted laser
desorption ionisation time-of-flight mass spectrometry (MALDI-
TOFMS) and surface-enhanced laser desorption ionisation time-
of-flight mass spectrometry (SELDI-TOFMS) technology have the
potential to identify patterns or changes in thousands of proteins
and can globally analyse almost all small molecular weight proteins
in complex solutions such as serum or plasma.
The aim of the present study was to identify proteins
differentially expressed in the serum of ovarian cancer patients
at different pathological grades. Proteins found differentially
expressed in the serum of ovarian cancer patients after the
depletion of high abundance proteins (including albumin and
immunoglobulins) were analysed and compared to normal serum
using proteomic approaches. A subset of common proteins
significantly elevated in grade 1, 2 and 3 of cancer patients were
identified by nano-electrospray quadrupole quadrupole time-of-
flight mass spectrometry (n-ESIQ(q)TOFMS) and MALDI-TOFMS
as a series of haptoglobin-1 precursor (HAP1). This method not
only provides efficient profiling of low abundance differentially
expressed serum proteins in cancer patients but also allows
proteomic-based identification of circulating proteins that have
the potential to be used as early-stage markers.
MATERIALS AND METHODS
This study was approved by the Royal Women’s Hospital,
Melbourne, Research and Human Ethics Committee (Human
Ethics Committee # 02/29 and 02/30). Human blood was collected
from healthy volunteers (n¼8) and patients (n¼38) presenting at
the Oncology/Dysplasia Unit, Royal Women’s Hospital, Mel-
bourne, after the provision of a participant information statement
and with informed consent. The mean age of women in the control
group and women with ovarian cancer was 47 and 62 years,
respectively. Of the six patients with grade 1 ovarian cancer four
had stage 1, one stage 2 and one had stage 3 disease (Table 1). Two
patients with stage 1, one with stage 2 and five with stage 3 ovarian
cancer were included in grade 2 group. All patients, except two
with grade 3 ovarian cancer had stage 3 disease. The remaining two
patients in grade 3 were diagnosed with stage 4 ovarian cancer
(Table 1).
Ovarian cancer patients with serous, mucinous, endometrioid
and clear-cell carcinoma subtypes were included in the study
(Table 1). One patient diagnosed with Brenner tumour was also
included in the study (Table 1). Of the six patients in grade 1
group, four were diagnosed with endometrioid tumour and the
other two had mucinous tumours. Grade 2 patients comprised of
four serous and four endometrioid subtypes. Nine serous and 13
endometrioid subtypes of patients were included in grade 3
subgroup. One clear-cell carcinoma and one Brenner tumour
subtype was also included in the group. Serum samples were
collected from patients after diagnoses and before surgery. All
ovarian cancer patients except three had CA 125 values above the
cutoff limit of 35Uml
 1 (Table 1). All patients except two in grade
1 group with a clinical diagnoses of stage 1 and 2 and one grade 3
patient at stage 3 presented with ascites.
Whole blood (10ml) was collected by venepuncture into plain
collection tubes for serum (blood was allowed to clot at room
temperature for 30min). Samples were centrifuged at 2000g for
10min after which serum was collected. An aliquot (100ml) was
removed for the determination of total protein. Serum was stored
at  801C until analysed.
Protein assay
Total protein content was determined using a commercial protein
assay kit with BSA standards according to the manufacturer’s
instruction (Pierce, Rockford, IL, USA).
Affi-gel Blue and protein A treatment
Human serum samples were treated with a mixture of Affigel-Blue
and protein A (5:1) in the form of a spin column. The spin
columns containing a mixture of Affi-Gel Blue and Protein A
selectively bind and remove albumin and immunoglobulin
Table 1 Description of ovarian cancer patients participating in the
proteomic study
Case
no.
Histological
grade
Clinical
stage
Tumour
subtype
CA 125
(Uml
 1)
23 1 2B Endometrioid 27
24 1 3C Mucinous 281
57 1 1A Endometrioid 37
98 1 1B Endometrioid 786
121 1 1C Endometrioid NA
2 1 1C Mucinous 93
11 2 2B Serous 172
28 2 3C Endometrioid 93
42 2 3C Endometrioid 12
54 2 1C Endometrioid 711
73 2 1C Endometrioid 15
76 2 3C Serous 681
86 2 3C Serous 333
183 2 3C Serous 3471
3 3 3C Endometrioid 307
31 3 3C Endometrioid 996
40 3 4 Endometrioid 3571
51 3 3C Endometrioid 10384
77 3 3C Endometrioid 56
108 3 2C Endometrioid 93
116 3 3C Endometrioid 255
148 3 3C Endometrioid 883
160 3 3C Endometrioid 61
168 3 3C Endometrioid 137
19 3 3B Serous 126
20 3 3C Brenner tumor 123
39 3 3C Serous 682
83 3 2B Endometrioid 165
103 3 3C Clear cell carcinoma 833
122 3 3C Endometrioid 2112
156 3 3C Endometrioid 659
163 3 3C Serous 177
164 3 4 Serous NA
172 3 3C Serous 1308
182 3 2C Serous NA
184 3 3C Serous 353
185 3 3C Serous 682
196 3 3C Serous 5437
NA¼not available.
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1ml of binding buffer (20mM phosphate buffer, pH 7.0) by
centrifugation for 20s at 1000g. In all, 50ml of serum was added to
150ml of binding buffer and mixed by vortex and loaded on the
spin columns. Following incubation at room temperature for 1h,
columns were centrifuged for 20s at 1000g to collect the eluate.
The columns were washed with 200ml of the binding buffer and
combined with the first eluate to form the depleted serum sample.
The total protein concentration of the combined eluate was
determined. The eluate was stored at  801C until further analysis.
Two-dimensional electrophoresis
First-dimension separation In total, 25mg of serum protein was
mixed with rehydration buffer (7 M urea, 2 M thiourea, 100mM
DTT, 4% CHAPS, 0.5%. carrier ampholytes pH 4–7, 0.01% BPB
and 40mM Tris) to a final volume of 200ml and incubated for 1h at
room temperature. This mixture was then applied to a Ready
Strip
s (11cm, pH 4–7, Bio-Rad Laboratories, USA) and actively
rehydrated at 50V at 201C for 16h. Serum proteins were
isoelectrically focused at 250V for 15min and then slowly ramped
up to 8000V for 150min and then maintained at 8000V for a total
of 35000Vhgel
 1. (i.e. a total of 42000Vh per gel). Ready Strips
were then stored at  801C until second-dimension processing.
Second-dimension separation Ready Strips from the first-dimen-
sion separation were equilibrated in 5ml of equilibration buffer
(50mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 0.01%.
BPB, 2mM tributyl phosphine (TBP)). Strips were rinsed in Tris
glycine SDS running buffer (25mM Tris, 192mM glycine, 0.1%
wv
 1 SDS pH 8.3) and then applied to the top of a 10% Tris-HCl
Precast Criterion Gel (Bio-Rad Laboratories, USA). Low melting
point agarose (0.5% in running buffer containing BPB) was layered
on top of the strip. Molecular weight markers were run
simultaneously. Electrophoresis on the gel was carried out at
10mAgel
 1 for 1h, 20mAgel
 1 for 2h and then 30mAgel
 1 for
30min. Gels were then fixed in methanol/acetic acid (40%/10% in
dH2O) for 1h at room temperature and then incubated in SYPRO
Ruby
s (Bio-Rad laboratories, USA) for 16h at room temperature
on a rocking platform. Gels were destained for 1h in methanol/
acetic acid (10%/7% in dH2O), imaged using a Bio-Rad FX imager
at 100nm resolution and analysed using PDQuest version 6. The
computer program identified protein spots from the digital images
of the gel. Some serum samples were repeated three times to assess
the variability between the experiments on different gels.
Mass spectrometry Coomassie-stained proteins were excised
from gel, and then digested with trypsin. Mass spectrometry
analyses were preformed on an Ettan MALDI-TOF (Amersham
Bioscience, UK) and API QSTAR Pulsar i Mass spectrometer
(Applied Biosystems, MDS Sciex, Framingham, USA). TOFMS data
were searched via PepSea Server, which is included in the Analyst
Software (Applied Biosystems, MDS Sciex, Framingham, USA).
Tandem MS data were searched via the Mascot search engine.
Western blotting
Serum samples separated by first and second dimension as
described earlier were transferred to nitrocellulose membranes.
Membranes were probed with anti-haptoglobin (mouse mono-
clonal, Sigma, St Louis, USA) followed by peroxidase-labelled
secondary antibody and visualised by the ECL (Amersham, UK)
detection system according to the manufacturer’s instructions.
Immunohistochemistry
Paraffin processed archival tissues were obtained from the
Department of Pathology, Royal Women’s Hospital, Melbourne.
These included normal ovaries (n¼6) needed for control
comparisons, which were removed from patients undergoing
surgery as a result of suspicious ultrasound images, palpable
abdominal masses and family history. The pathology diagnosis and
tumour grade was determined by two staff pathologists in the
Department of Pathology, Royal Women’s Hospital, Melbourne.
The classification of the tumours was carried out as part of the
clinical diagnosis. Histological grading of ovarian carcinoma was
carried out by the method described by Silverberg (2000).
Tissue sections were cut at 4mm thickness, mounted on Poly-L-
lysine-coated slides and incubated for 1h at 601C. Sections were
brought to water through three changes each of xylene and
ethanol. Antigen unmasking was undertaken using citrate buffer
(pH 6.0) in a microwave oven. Endogenous peroxidases were
removed using 3% hydrogen peroxide in methanol and endogen-
ous biotin activity was blocked using a sequence of diluted egg
white (5% in distilled water) and diluted skim milk powder (5% in
distilled water). Sections were incubated for 1h in haptoglobin
monoclonal antibody (Sigma, St Louis, USA) diluted 1:10000 in
1% BSA in Tris buffer (100mM pH 7.6). Antibody binding was
amplified using biotin and streptavidin HRP (DAKO, Denmark)
for 15min each and the complex was visualised using diamino-
benzidine (DAB). Nuclei were lightly stained with Mayer’s
haematoxylin. An isotype IgG1, suitably diluted, was substituted
for the antibody as a negative control.
Sections were assessed microscopically for positive DAB
staining. The extent of haptaglobin expression was scored as 0
(o10%), 1 (11–25%), 2 (26–50%), 3 (51–75%), 4 (76–90%) and 5
(490%). In addition to the extent of staining, tissue and cellular
distribution of staining was determined.
RESULTS
Removal of high abundant proteins from human serum
Figure 1A demonstrates a typical two-dimensional gel electro-
phoresis (2DE) human serum profile evidenced by SYPRO-Ruby
staining. More than 300 proteins were detected and localised
between pI 4–7 and molecular mass range of 20–200kDa. The
albumin smear at around 68kDa was present in untreated serum
but within 1h of Affi-Gel Blue and protein A treatment, significant
removal of albumin was achieved with no apparent significant loss
of other proteins displayed (Figure 1). Concomitant with the
removal of albumin there was a significant enhancement in the
staining intensity of several protein spots (Figure 1B). These
results suggest that Affi-Gel Blue and protein A treatment of
human serum results in the removal of high abundance albumin,
thereby increasing the detection of low abundance proteins that in
the presence of albumin would have remained obscured. We have
implemented this approach of albumin clearance for the identi-
fication of differentially expressed low abundance proteins in the
serum of ovarian cancer patients.
Serum protein profile of ovarian cancer patients at
different histological grades
Protein profiles on the serum of grade 1 (n¼6), grade 2 (n¼8)
and grade 3 (n¼24) ovarian cancer patients were analysed by 2-
DE and visualised by staining with SYPRO-Ruby. These profiles on
replicate sets were compared with the serum of normal healthy
women (n¼8) using PDQuest software with the representation of
the Gaussian profile shown in Figure 2A–C. The quantitative
evaluation of the differentially expressed serum proteins in normal
vs grade 1, grade 2 or grade 3 ovarian cancer patients was
performed by using Student’s t-test. Significant differences in the
overall profiles of serum proteins were obtained in grade 1, 2 and 3
ovarian cancer patients compared to normal healthy volunteers.
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tially expressed in the serum of grade 1 ovarian cancer patients
(Figure 2A). Of these proteins, 15 proteins were upregulated by
two-fold, four proteins by five-fold and two proteins by 10-fold. In
contrast, one protein was downregulated by two-, five- and 10-fold,
respectively. In grade 2 cancer patients, differential expression of
31 proteins was observed of which 25 were upregulated by two-
fold, four by five-fold and two by 10-fold. Analysis of serum from
grade 3 cancer patients demonstrated two-fold downregulation of
13 proteins out of 25 differentially expressed proteins (Figures 2B
and C). There was upregulation of six proteins by two-fold, three
by five-fold and two by 10-fold, respectively. Among the
differentially expressed serum proteins in the three pathological
grades, 10 common proteins were consistently differentially
expressed in grade 1, 2 and 3 cancer patients (Po0.05). Not
unexpectedly, some proteins were found to be uniquely expressed
only in the serum of specific pathological grade of cancer patients
and were not consistently expressed among the three histological
grades of cancer patients. To ensure consistency in the observed
differential expression profile, serum samples from the same
patient prepared on three different days was repeated three times
and was investigated to eliminate confounding factors that may
arise from sample handling. No substantial variation in the profile
of protein spots of the same sample repeated on different days was
detected.
Protein identification
Six protein spots with approximate molecular weights of 40kDa
and pI’s 5.9–6.6, all significantly overexpressed in the serum of
grade 1, 2 and 3 ovarian cancer patients, were selected for
identification and further analysis (Figures 2 and 3). The protein
spots (1–6) could be visualised on the SYPRO-Ruby and
Comassie-stained gels. The selected proteins were excised from
the gel, subjected to in-gel digestion and analysed by MALDI-
TOFMS and n-ESIQ(q)TOFMS. The resultant mass fingerprinting
spectra of tryptic digests from the six spots showed identical
fragmentation pattern of the peptides, indicating these as series of
same protein separating at different pI and/or molecular mass
(Figure 4). Corresponding spectra of the protein was used for
protein search in the NCBI and Swissprot database, using the
PepSea Server search program or was subjected to MS/MS analysis
and then searched through the MASCOT search engine. The six
protein isoforms were identified as haptoglobin-1 precursor
(HAP1) (NCBI accession number P00737), a protein with a
molecular mass of 38.42kDa and pI of 6.1–6.6. Haptoglobin-1
precursor is more than 90% homologous to circulating haptoglo-
bin, a liver glycoprotein found in normal serum (Beutler et al,
2002). Peptide sequence obtained encompassed amino-acid
sequence corresponding to different region of HAP1 and is shown
in Table 2. The identity of HAP1 was further confirmed by 2-DE
Western blotting on the serum from healthy volunteers and grade
1 and 3 ovarian cancer patients using monoclonal anti-human
haptoglobin antibody that binds to an epitope within HAP1. The
antibody recognises both native and denatured human haptoglo-
bin in biological fluids. High immunoreactivity was observed with
the set of six proteins at 40kDa molecular weight by 2-DE Western
blot (Figures 5A–C). The six isoforms of HAP1, exhibited as a
chain of protein spots with slightly different molecular mass and
different pI’s, suggest post-translational modifications.
Immunohistochemistry analysis of HAP1-like acitivity
Overexpression of proteins on cancer cells can result in their
shedding in the peritoneum and hence absorption in the
circulation (Sedlaczek et al, 2002). We evaluated the expression
of HAP1-like immunoreactivity in normal and ovarian cancer
tissues. No expression of HAP1-like immunoreactivity was evident
in normal ovarian surface epithelium or stroma but some staining
was observed in the blood vessels of two cases (n¼6) (Table 3,
Figure 6A). However, moderate to strong epithelial staining of
HAP1-like reactivity was observed in ovarian tumours (n¼24,
seven grade1, nine grade 2 and eight grade 3) (Table 3, Figure 6B–
D). Staining was confined to epithelium, blood vessels and stroma.
Cellular staining was mostly cytoplasmic with the majority of the
staining being observed in scattered cell groups. Tumours with a
glandular pattern tended to have more staining. Strong staining
was evident in areas with myxomatous stroma, vascular spaces as
well as ovarian vessels. An isotype antibody used as a negative
control showed no HAP 1-like staining in normal or tumour
tissues.
DISCUSSION
Better prognosis of ovarian cancer relies on its early detection.
Biomarkers are hallmark for cancer detection and the serum
proteome of the cancer patient is a rich source of biomarkers due
to its modification with disease progression. Within the cancer,
cell proteome proteins that are overexpressed by the cells and then
released into the bloodstream are ideal markers for early detection
and can be used alone or in combination with other tumour
markers for screening approaches. Recently, transcriptional
profiling or the related serial analysis of gene expression,
subtractive hybridisation and differential display technologies
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Figure 1 Two-dimensional gel electrophoresis profile of (A) untreated
serum and (B) Affi-Gel Blue and protein A-treated human serum. Human
serum was treated with Affi-Gel Blue and protein A (5:1) on a column for
1h before analysis by 2-DE. Protein (50mg) was loaded on each gel. Results
are representative of three independent experiments.
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yhave identified 14 candidate ovarian tumour markers (Schummer
et al, 1999; Mok et al, 2001). Among those proteins, mesothelin
and kallikrein 10 were identified by monoclonal antibody and
candidate gene approaches, respectively (Scholler et al, 1999; Luo
et al, 2001). Mesothelin is elevated in the serum of 76% ovarian
cancer patients (Diamandis et al, 2000) and kallikrein 10 is
elevated in 56% of ovarian cancer patients (Luo et al, 2001). Both
mesothelin and kallikrein 10 may complement CA 125, increasing
the prospect of detecting ovarian cancer at an early, curable stage.
Gene array technology has recently identified prostasin (a serine
protease, previously identified in prostatic secretions), osteopontin
(a secreted bone morphogen) and creatine kinase B (a marker for
renal and lung cancers) to be elevated in serum from patients with
ovarian cancer (Mok et al, 2001; Kim et al, 2002). These data
indicate that screening approaches at the DNA, RNA or protein
level may identify a series of markers that have the potential to
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Figure 2 Depiction of the reference profile of all protein spots identified by 2-DE. Profile of proteins differentially expressed (in red) in the serum of (A)
grade 1 (n¼6), (B) grade 2 (n¼8) and (C) grade 3 (n¼24) ovarian cancer patients. Comparison between normal (n¼8) and each pathological grade of
cancer patients’ serum was made on replicate sets using PDQuest software.
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ycomplement the currently used marker for more specificity and
sensitivity.
Recently, Petricoin et al (2002) reported the application of
serum proteomic pattern profiling as a diagnostic tool for ovarian
cancer. Even though the approach has gained much attention, it is
still under evaluation for application to early-stage detection
because of its low specificity (B94%) (Petricoin et al, 2002). The
approach by Petricon et al does not require the identity of
individual components of the serum protein for use as a potential
diagnostic marker, but focuses mainly on the relative differences of
the protein profile of cancer patients compared to healthy
volunteers. The present study, however, focuses not only on
identifying a proteomic profile of moderate abundance proteins
representative of ovarian cancer patients but also attempts to
identify ovarian cancer-specific proteins that can be used as
biomarkers for early-stage screening.
Even though proteomic approaches have been utilised to
discover and identify novel proteins as potential diagnostic/
prognostic biomarkers, the technology has been limited by the
presence of high abundance proteins such as albumin and
immunoglobulin, which can mask or considerably decrease the
sensitivity of detection of several low abundant potential
biomarkers. Recently, we have demonstrated that the use of Affi-
Gel Blue and Aurum kit (Bio Rad Laboratories, USA) results in the
removal of highly abundance albumin and simultaneously
enhances the detection of several low abundance proteins (Ahmed
et al, 2003). In this study, we used columns containing a mixture of
Affi-Gel Blue and protein A (5:1) that is equally effective in
removing high abundance albumin. Removal of albumin is
achieved with minimal nonspecific protein removal and results
in the generation of a protein profile representative of low
abundance protein that can be used as a discriminator of a
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Figure 3 Elevated expression of protein spots 1–6 in the serum of ovarian cancer patients compared to serum from healthy volunteers. Image analysis
was performed by using PDQuest software. (A) normal serum, (B) grade 1, (C) grade 2 and (D) grade 3 ovarian cancer patients.
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Figure 4 TOFMS spectra obtained for the six HAP1 protein spots. After trypsin digestion, peptide fragments were analysed by n-ESIQ(q)TOFMS in
TOFMS and tandem MS mode. (A–F) Demonstrates the TOFMS spectra of protein spots 1–6. Database searching using the Pep Sea software allowed the
identification of the six spots as isoforms of HAP1 (Swissprot accession number P00737). Sequence data are presented in Table 2.
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Figure 4 (Continued).
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yparticular disease state. Hence, by using such techniques for
sample processing before 2-DE analysis, one can increase the
likelihood of discovery of novel biomarkers of high sensitivity and
specificity.
Significant differences in the serum protein profiles of grade 1, 2
and 3 ovarian cancer patients (n¼30) was obtained compared to
that of healthy volunteers (n¼8). Several proteins were found to
be differentially or uniquely expressed in the serum of a specific
pathological grade of cancer patients and were not consistently
expressed among all the histological grades of cancer patients.
Compared to healthy volunteers, 24 proteins were differentially
expressed in the serum of grade 1 ovarian cancer patients. Grade 2
cancer patients showed differential expression of 31 proteins while
that in grade 3 cancer patients 25 proteins were significantly
different. Among the differentially expressed serum proteins, 10
common proteins were consistently expressed in grade 1, 2 and 3
cancer patients (Po0.05). Six of the common proteins with
approximate molecular weights of 40kDa and pI’s 5.9–6.6 were
significantly overexpressed in the serum of grade 1, 2 and 3
ovarian cancer patients. These proteins were selected for
identification by n-ESIQ(q)TOFMS and MALDI-TOFMS analysis.
Mass fingerprinting spectra from the six proteins showed identical
fragmentation patterns of the peptides, suggesting the possibility
of post-translational modification of a single protein separating at
different pI and/or molecular mass. MS/MS analysis of the six
proteins confirmed their identity as isoforms of HAP1 (Swissprot
accession number P00737), a protein with a molecular mass of
38.42kDa and pI of 6.1–6.6 that shares 90% homology to a liver
glycoprotein haptoglobin, present in the normal serum. Further
confirmation of HAP1 was obtained by Western blotting using
monoclonal anti-human haptoglobin antibody. The six isoforms of
haptoglobin-1 precursor exhibited on 2-DE Western blot as a chain
of protein spots with slightly different molecular mass and
different pI’s.
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Figure 5 2-DE Western profile of protein spots 1–6 in (A) normal, (B) grade 1 and (C) grade 3 ovarian cancer patients by using monoclonal-anti
haptoglobin. Serum samples were resolved for first and second dimensions as described in the Materials and Methods section.
Table 2 Peptides (underlined) from spots 1–6 corresponding to
haptoglobin-1 precursor molecule
MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIA 40
HGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVG 80
DKLPECEAVCGKPNPANPVQR
103ILGGHLDAK
111GSFPWQAKM 120
VSMMNLTTGATLINEQWLLTTAKNLFLNHSENATAK
157DIAP 160
TLTLYVGK
168KQ LVEIEKVVLHPNYSQVDIGLIKLNQKVSVN 200
E
202RVMPICLPSKDYAEVGRV
219GYVSGWGRNANFKFTDHLK
239YV 240
MLPVADQDQCIRH
253YEGSTVPEKKTPK
266SPVGVQPILNEHTF 280
CRGMSK
286 287YQEDTCYGDAAGSAFAVHDLEEDTWYATGILSFDK
320 320
SCAVAEYGVYVKVTSIQDWVQKTIAEN
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thus preventing iron loss and renal damage (Wassell, 2000). The
native form of haptoglobin is a B90000kDa tetramer composed of
two nonidentical a- and b-subunits linked by intermolecular
disulphide bonds (Hanley and Heath, 1985). In vivo haptoglobin is
synthesised as a single polypeptide exhibiting a molecular weight
of 38000kDa that is proteolytically processed post-translationaly
to form the a- and b-subunits of the native protein (Haugen et al,
1981). The precursor protein contains NH2-terminal 18 residue
signal sequence before the a chain and/or intervening polypeptide
between the a- and b-regions (Misumi et al, 1983). In vivo post-
translational event results in the proteolytic removal of the signal
sequence and the incorporation of the core oligosaccharide side
chains into the b-region by membrane-associated enzyme systems
(Haugen et al, 1981). There is a possibility that post-translation
modification also results in the cleavage of both a- and b-regions
of the precursor polypeptide to form the native protein (Haugen
et al, 1981). The biological implications of the unique mode of
biosynthesis and processing of haptoglobin is still not clear but
pulse chase experiments have shown that a substantial proportion
of the newly synthesised haptoglobin is secreted as a single-
polypeptide precursor (Misumi et al, 1983). As haptoglobin is
among the most abundant glycoproteins secreted by the liver, it is
reasonable to hypothesise that enhanced hepatic synthesis of the
protein will occur due to an acute phase response in ovarian cancer
patients resulting in elevated serum haptoglobin precursor
concentration. As most secreted proteins are initially synthesised
as larger precursor with an extended NH2-terminal sequence that
is cleaved at the late-stage secretory process either within the Golgi
complex or related vesicles (Schreiber and Urban, 1978), one can
assume that the elevation of the HAP1 in cancer patients serum
may result due to a disease-specific defective intracellular
processing.
Differences in the glycosylation pattern of the protein have the
potential to change both the pI and molecular mass of the protein
Table 3 Extent of haptoglobin staining in normal ovarian and tumour
tissues
Grade Case no Clinical stage Haptoglobin staining
Normal 11 0
17 0
19 0
28 0
31 0
37 0
Grade 1 6 1A 3
51 1B 4
62 1B 2
83 1C 2
106 3C 1
164 1A 3
190 1A 2
Grade 2 32 1A 2
35 3C 2
46 4 2
49 NA 3
110 3C 2
121 3C 2
129 3C 4
161 1C 1
188 1A 3
Grade 3 2 3C 2
33 C 2
44 2B 2
90 3C 2
96 3C 3
143 4 2
146 4 3
153 4 2
The extent of haptaglobin staining in normal ovaries and in tumours was assessed in
epithelium, stroma and ovarian cells and scored as 0 (o10%), 1 (11–25%), 2 (26–
50%), 3 (51–75%), 4 (76–90%) and 5 (490%). NA¼not available.
Figure 6 Expression of HAP1-like immunoreactivity in ovarian tissues. Sections of the normal and malignant ovarian tissues were stained by the
immunoperoxidase method for the expression of HAP1-like activity as described in the Materials and Methods. (A) HAP1-like activity in normal ovary; (B)
in endometriod grade 1 ovarian tumour, (C) serous grade 2 ovarian tumour and (D) serous grade 3 ovarian tumour. Arrows indicate the expression of
HAP1-like activity in epithelial cells, myxomatous stroma and ovarian vessels.
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haptoglobin have been demonstrated in the normal serum using
2-DE approach (Wilson et al, 2002). These observations are
consistent with our results demonstrating six different isoforms of
HAP1 in the serum of ovarian cancer patients. As the native
protein has 90% homology to the precursor, the visualisation of
HAP1 on 2-DE Western blot by monoclonal-anti-haptoglobin is
not unexpected.
Elevated concentrations of serum haptoglobin were reported
in ovarian cancer patients in the early seventies (Mueller et al,
1971). Haptoglobin level was shown to be affected by the amount
of tumour burden and was not dependent on the histologic type
or grade of ovarian malignancy (Mueller et al, 1971). Some studies
have shown increased fucosylation and other carbohydrate
changes in serum haptoglobin of ovarian cancer patients
(Thompson et al, 1992b). Strong association between abnormally
fucosylated haptoglobin and a 1,3 fucosyltransferase activity
has been demonstrated in the blood specimens of ovarian
cancer patients (Thompson et al, 1992a). Recently, correlation
between haptoglobin, CA 125 and interleukin-6 have been
shown in ovarian cancer (Dobryszycka et al, 1999). As these
studies relied on spectrophotometric (Mueller et al, 1971),
immunodiffusion (Thompson et al, 1992b) and electrophoretic
methods (Thompson et al, 1992a) for the detection of haptoglobin,
it is not surprising that homologous native protein was detected
rather than the precursor. Another recent study has shown
haptoglobin a-subunit as potential serum biomarker in ovarian
cancer (Ye et al, 2003).
In this study, we also report enhanced expression of HAP1-like
activity in ovarian tumours. No immunohistochemical expression
of HAP1 was evident in normal ovarian surface epithelium or
ovarian stroma. On the other hand, moderate to strong epithelial
and stromal staining of HAP1-like activity was observed in ovarian
tumours (grades 2 and 3). Epithelial staining was mostly
cytoplasmic with majority of the staining being observed in
scattered cell groups. Interestingly, strong staining was evident in
the myxomatous stroma of malignant ovaries as well as ovarian
vessels. These results suggest that HAP1-like expression is present
in ovarian tumours but it is the predominant circulating hepatic
haptoglobin that is significantly elevated in the serum of ovarian
cancer patients.
In conclusion, we present the first evidence that serum HAP1 is
significantly increased in early-stage ovarian cancer patients. We
suggest that HAP1 may constitute a new and useful biomarker for
ovarian cancer diagnosis. These data however need confirmation
with further prospective clinical studies.
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